Candel Therapeutics Inc

NASDAQ:CADL

9.98

-0.34 (-3.30%)

Market Cap (Intraday)	286.31M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.01 Million
Adjusted EPS	-$0.31

See more estimates

10-Day MA	$10.39
50-Day MA	$10.37
200-Day MA	N/A

See more pivots

Candel Therapeutics Inc Stock, NASDAQ:CADL

117 Kendrick Street, Suite 450, Needham, Massachusetts 02494

United States of America

Phone: +1.617.916.5445

Number of Employees:

http://www.candeltx.com

Description

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.